Roivant's experimental lung disease drug meets goals in mid-stage study | Reuters

Roivant lung disease drug meets Phase 2 goals, shares surge 20%

Roivant Sciences reported its experimental inhaled drug for interstitial lung disease met primary endpoints in a mid-stage trial for pulmonary hypertension, with shares rising about 20% on the news.